NCT05551598已完成2 期
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2022年11月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Time to First Protocol-defined Relapse
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled Phase Ⅱ study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with neuromyelitis optica spectrum disorder (NMOSD). Participants will be randomly enrolled into three groups: Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group, and Placebo group. The primary outcome measure is time to first protocol-defined relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-60 years (inclusive) at the time of signing the informed consent form, both men and women;
- •Participants meet the 2015 international consensus diagnostic criteria for neuromyelitis optica spectrum disease (NMOSD) and are AQP4-IgG positive or negative (acceptable test results within 24 weeks before signing the informed consent form);
- •Experienced at least 2 attacks within 1 year before screening and/or at least 3 relapses in the past 24 months, but have at least 1 documented clinical evidence of attack or relapse (including the first attack) within 12 months before screening;
- •Expanded disability status scale (EDSS) ≤ 7.5 points at screening and baseline retest;
- •Participants voluntarily sign the informed consent form and voluntarily complete the trial according to the protocol requirements.
排除标准
- •Pregnant or lactating female participants, or participants planning to have a child during the study;
- •Any surgical procedure within 4 weeks before randomization, with evidence of other demyelinating diseases or progressive multifocal leukoencephalopathy (PML);
- •Known active infection (excluding nail bed fungal infection or dental caries) within 4 weeks before randomization;
- •Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV antibody) is positive;
- •History of drug or alcohol abuse or mental disorder within 1 year before randomization;
- •Evidence of active tuberculosis (TB; excluding patients receiving drugs to prevent latent TB infection);
- •Evidence of active interstitial lung disease;
- •Receipt of any live or live attenuated vaccine within 6 weeks before randomization;
- •History of malignancy, including solid tumors, hematological malignancies, and carcinoma in situ (except completely resected and cured basal cell carcinoma and squamous cell carcinoma or cervical carcinoma in situ) within the past 5 years;
- •History of severe drug allergy, allergy or intolerance to Mitoxantrone and liposomes (shock, allergic reactions);
- •Participants with other chronic active immune system diseases other than NMOSD or stable disease but requiring high-dose glucocorticoid maintenance therapy: such as rheumatoid arthritis, scleroderma, Schogren' s syndrome, ulcerative colitis, genetic immunodeficiency or drug-induced immunodeficiency; participants with positive autoantibodies only but without clinical manifestations can be enrolled in the trial;
- •Participants with other diseases not suitable for this study as judged by the investigator;
- •Received any investigational agent within 3 months prior to randomization, or participated in a medical device clinical study and judged by the investigator to have a potential impact on the results of this trial;
- •History of prior NMOSD therapy with any of the following: a. received prior mitoxantrone or anthracycline therapy, total body irradiation, or bone marrow transplantation at any time; b. received rituximab or any experimental B-cell depleting agent within 6 months prior to randomization, unless the participant had a B-cell count higher than LLN in the central laboratory; c. used any of the following within 3 months prior to randomization: Satralizumab,Tocilizumab,inebilizumab,Eculizumab,Alemtuzumab,Ciclosporin,Azathioprine,Cyclophosphamide,Tacrolimus,Mycophenolate mofetil. Any other treatment to prevent relapses in multiple sclerosis (MS) (eg, Interferon, Natalizumab, Glatiramer acetate, Fingolimod, Teriflunomide, or Dimethyl fumarate); d. intravenous immunoglobulin (IVIG) therapy, plasma exchange therapy (PE) within 1 month prior to randomization; e. participants who are receiving oral corticosteroids at doses higher than 30 mg/day in prednisolone conversion; f. anti-CD4, cladribine within 2 years prior to randomization.
- •Presence of the following clinically significant diseases: a. cardiac ejection fraction (EF) less than 50% by echocardiography or lower than the lower limit of laboratory values at the study site; history of chronic congestive heart failure, cardiac function NYHA class Ш ~ Ⅳ; b. any of the following events within 3 months before randomization: myocardial infarction, acute coronary syndrome, viral myocarditis, pulmonary embolism, stroke; coronary revascularization within 6 months; c. screening ECG showed QTc interval > 480 ms (according to Fridericia correction formula, QTc = QT/RR^0.33), or a history of severe QTc prolongation.
- •Patients with the following abnormalities in laboratory values during screening: a. aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN), alanine aminotransferase (ALT) > 3 × ULN, total bilirubin > 1.5 × ULN (unless due to Gilbert 's syndrome); b. platelet count < 50,000/μL (or < 50 × 10^9/L), hemoglobin < 9 g/dL (or < 90 g/L), white blood cells < 2.0 × 10^3/μL, absolute neutrophil count < 1.0 × 10^3/μL; c. creatinine clearance (CLcr) < 60 mL/min (calculated using the Cockcroft-Gault formula: [140 - age (years)] × [body weight (kg)] × (0.85, if female)/[72 × serum creatinine (mg/dL)]) or receiving dialysis during screening;
研究组 & 干预措施
Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group
Experimental
干预措施: Mitoxantrone Hydrochloride Liposome Injection (Drug)
Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group
Experimental
干预措施: Mitoxantrone Hydrochloride Liposome Injection (Drug)
Placebo Injection every 12 weeks (Q12W).
Placebo Comparator
干预措施: Mitoxantrone Hydrochloride Liposome Injection (Drug)
结局指标
主要结局
Time to First Protocol-defined Relapse
时间窗: Up to Week 48
Time to First Protocol-defined Relapse was defined as time from randomization to first occurrence of relapse. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neuromyelitis optica spectrum disorder (NMOSD).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of CM310 in Subjects With Chronic PruritusChronic Pruritus of Unknown OriginNCT05452343Keymed Biosciences Co.Ltd50
尚未招募
2 期
Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisChronic Rhinosinusitis With Nasal PolypsNCT06372678Keymed Biosciences Co.Ltd90
已完成
2 期
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle WeaknessMyasthenia GravisNCT02965573argenx24
已完成
2 期
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisModerate to Severe Plaque PsoriasisNCT06109818Beijing InnoCare Pharma Tech Co., Ltd.129
已完成
2 期
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 PneumoniaCOVID-19 PneumoniaNCT04386616Genentech, Inc.396